Rashes temsirolimus

Temsirolimus (Torisel Kit) [mTOR Inhibitor] Uses Advanced RCC Action mTOR inhibitor Dose 25 mg IV over 30-60 min x 1 wk continue until tox or progression pre med w/ 25-50 mg Benadryl 30 min before Caution [D, -] w/ CYP3A4 inhib/inducers (Table VI-8), avoid grapefruit juice, vaccines, immediately postop Contra None Disp IV SE Hypersensitivity Rxn, rash, asthenia, mucositis, N, edema, anorexia, poor wound healing, bowel perfusion EMS May T glucose OD May cause NA, abd pain, HA, confusion, melana, and Szs symptomatic and supportive... 

The promising second oral therapy is Temsirolimus (Wyeth Pharm). Temsirolimus is believed to block the proliferation of immune T cells activated by interleukin, IL-2. The phase It clinical trial of Temsirolimus was also an international double blind placebo controlled trial. The trial involved 296 patients with either RR MS or SP MS with relapses. Participants received one of three doses of oral temsirolimus or placebo daily for 9 months. The primary outcome measure was the number of enhancing lesions after 9 months in study. By 32 w eeks into the study, those in the highest treatment dose had 47.8% fewer new enhancing lesions compared to those on placebo. The high dose group also had 51 % fev er relapses than the placebo group. Side effects included mouth ulceration or inflammation, menstrual dysfunction, hyperlipidemia and rashes. 

Skin A 73-year-old woman with metastatic renal cell carcinoma developed a pruritic rash after receiving two infusions of temsirolimus 25 mg/week the rash was located on both antecubital areas and the backs of the knees [105 ]. Biopsy showed spongiotic dermatitis with eosinophils. The authors hypothesized that temsirolimus, an mTOR kinase inhibitor, has a direct inhibitory effect on signalling pathways that regulate cell growth and tissue repair. 

Gandhi M, Kuzel T, Lacouture M. Eosinophilic rash secondary to temsirolimus. Clin Genitourin Cancer 2009 7(2) E34-6. 

Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus a systematic review of the literature and meta-analysis. Eur J Cancer February 2012 48(3) 340-6. PubMed PMID 22206873. Epub 2011/12/31. eng. 

---